RxDoctor Payments Data

David Scheider, MD

Gastroenterology · Lone Tree, CONPI 1538273776

Payments from drug & device makers

$4,020in general payments, 2019–2025

Across 176 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$475
  • Takeda Pharmaceuticals U.S.A., Inc.$419
  • Gilead$283
  • Bristol Myers Squibb$235
  • Johnson & Johnson$232
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,020100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,020 in reported general payments places this provider in the 60th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$257,898
Medicare patients
355
Services billed
8,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase37$43,060
XifaxanRifaximin11$18,774
SutabSod Sulf/Pot Chloride/Mag Sulf90$14,743
Budesonide DrBudesonide68$12,775
LinzessLinaclotide11$7,714
Mesalamine12$4,239
Colestipol Hcl28$2,978
Pantoprazole Sodium224$2,826
Mesalamine ErMesalamine17$2,729
Ursodiol13$2,371
Esomeprazole Magnesium41$1,669
Rabeprazole Sodium47$1,568
Famotidine50$1,493
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$1,230
Dicyclomine Hcl49$1,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,343$50,77348 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$475$18,77411 claims
Braintree Laboratories, Inc.Sutab$31$14,74390 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Lone Tree

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →